19P Long-term fatigue after treatments for non-epithelial ovarian cancer survivors

Non-epithelial rare germ cell tumors (GCT) and sex cord stromal tumors (SCST) are mainly associated with long survival. The treatment includes surgery, frequently combined with chemotherapy (CT). The French Rare Malignant Gynecological Tumors (TMRG)/GINECO case-control VIVROVAIRE Rare tumors study already reported the QOL among survivors, treated with surgery +CT, compared to age-matched healthy women (HW). Looking to the different clinical profile of pts, we intend to describe the long-term fatigue according to subtype of cancers (SCST, GCT). Non-epithelial ovarian cancer survivors (nEOCS), cancer-free ≥2 years after treatment, were identified from the TMRG Network. HW were issued from the 'Seintinelles' research platform. Primary endpoint was chronic fatigue (MFI) compared between patients (SCST/GCT) versus HW. A minimal 5% difference for the score between groups was considered as clinically relevant. 97 SCST and 120 GCT were included. Patients' characteristics are detailed in the table. SCST patients were older than GCT and mostly FIGO stage I. Median delay from the end of treatment was 6 yrs. In univariate analysis, among SCST treated with CT, levels of general fatigue were significantly higher compared with HW (MFI general fatigue median score 27.0 [IQR: 21.0-31.0] vs 23.0 [17.3-27.8], p= 0.02). Among GCT treated with CT, fatigue was not different from HW (MFI general fatigue median score 24.0 [20.0-29.0] vs 23.0 [18.0-30.0], p= 0.592). After adjustment on age, schooling, BMI, insomnia and physical activity (IPAQ), fatigue remained significantly higher for all SCST, compared with all HW (beta= 1.67; p = 0.026); but not for SCST compared with age-matched HW (p=0.098). Table: 19PPatients' characteristics and levels of fatigueSCSTSCST treated with CTAge-matched HWGCTGCT treatedwith CTAge-matched HWNumber of patients97458612099198Median age (yrs)584950323333FIGOstage I73 (75%)24 (53%)60 (50%)40 (40%)stage II4 (4%)4 (9%)8 (7%)8 (8%)stage III10 (10%)9 (20%)30 (25%)30 (30%)NA10 (10%)8 (18%)22 (18%)21 (21%)MFI general fatigue median score27.0 [21.0-31.0]23.0 [17.3-27.8] p= 0.0224.0 [20.0-29.0]23.0 [18.0-30.0] p= 0.592 Open table in a new tab SCST patients (older pts compared to GCT) have long-term fatigue more than 6yrs after the end of treatments, which was not observed for GCT patients. This long-term fatigue need to be integrated in the follow-up care plan of nEOCS.